Holen Sie sich die Stockscreener-App
45.74
2.66%
-1.25
Handel nachbörslich:
45.74
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$46.99
Offen:
$47.29
24-Stunden-Volumen:
948.87K
Relative Volume:
0.86
Marktkapitalisierung:
$5.40B
Einnahmen:
$3.22M
Nettoeinkommen (Verlust:
$-576.40M
KGV:
-8.5019
EPS:
-5.38
Netto-Cashflow:
$-407.05M
1W Leistung:
-1.89%
1M Leistung:
-4.27%
6M Leistung:
-19.46%
1J Leistung:
-46.62%
1-Tages-Spanne:
$45.51
$47.42
1-Wochen-Bereich:
$44.49
$48.45
52-Wochen-Spanne:
$44.49
$86.63
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie CYTK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
45.74 | 5.40B | 3.22M | -576.40M | -407.05M | -5.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Cytokinetics' SWOT analysis: aficamten's potential drives stock outlook - Investing.com
Cytokinetics' SWOT analysis: aficamten's potential drives stock outlook By Investing.com - Investing.com Canada
Cytokinetics (NASDAQ:CYTK) Given "Market Outperform" Rating at JMP Securities - MarketBeat
S&P 500 Futures Rise in Premarket Trading; Trump Media & Tech, Cytokinetics Lag - Barron's
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030 - GlobeNewswire
Cytokinetics Sets FDA Review Date for Aficamten, Unveils Ambitious 2030 Global Expansion Plan - StockTitan
HC Wainwright Reiterates “Buy” Rating for Cytokinetics (NASDAQ:CYTK) - Defense World
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
Cytokinetics EVP sells shares worth $98,640 By Investing.com - Investing.com South Africa
Cytokinetics EVP sells shares worth $98,640 - Investing.com India
Cytokinetics (NASDAQ:CYTK) Sets New 1-Year LowTime to Sell? - MarketBeat
Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 2,000 Shares of Stock - MarketBeat
Cytokinetics (NASDAQ:CYTK) Receives Buy Rating from HC Wainwright - MarketBeat
Cytokinetics stock hits 52-week low at $45.59 amid market challenges - Investing.com Canada
Vanguard Group Inc's Strategic Acquisition of Cytokinetics Inc S - GuruFocus.com
Cytokinetics’ SWOT analysis: aficamten progress boosts stock outlook By Investing.com - Investing.com Nigeria
Cytokinetics' SWOT analysis: aficamten progress boosts stock outlook - Investing.com
Cytokinetics' SWOT analysis: aficamten progress boosts stock outlook By Investing.com - Investing.com Canada
Congestive Heart Failure Market Expected to rise, 2034 | Novartis, Boehringer Ingelheim, Eli Lilly, Bayer, Merck, AstraZeneca, Amgen, Otsuka Pharmaceutical, Cytokinetics, Mesoblast, Novo Nordisk - Barchart
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Cytokinetics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
10 Clinical Trials Of 2024 – Hits, Misses And Some In Between - News & Insights
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Cytokinetics Awards Stock Grants to New Employees, Including Options and Performance Units - StockTitan
Nvidia Corp (NVDA-Q) QuotePress Release - The Globe and Mail
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Principal Financial Group Inc. - MarketBeat
S&P 500 Futures Drop in Premarket Trading; Sportradar Group, Cytokinetics Lead - MarketWatch
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug - MSN
Cytokinetics' aficamten application validated by EU regulators - MSN
Cytokinetics' potential blockbuster heart drug flips to new partner in China - The Business Journals
Cytokinetics' Heart Drug Aficamten Advances with EMA Validation for Key European Review - StockTitan
Cytokinetics, Incorporated Announces Executive Changes - Marketscreener.com
Cytokinetics (CYTK) Stock Rises on New Licensing Deal - GuruFocus.com
Why Cytokinetics Stock Was a Nearly 5% Winner Today - MSN
Spinal Muscular Atrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and MOA, ROA by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme Corp - The Globe and Mail
Cytokinetics stock rises on Sanofi's rights acquisition By Investing.com - Investing.com Canada
HC Wainwright Reiterates "Buy" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
Sanofi: acquisition of aficamten rights for China - Marketscreener.com
Cytokinetics, Incorporated Announces Sanofi Acquires Exclusive Rights to Develop and Commercialize Aficamten from Corxel Pharmaceuticals - Marketscreener.com
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China - The Manila Times
Calculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK) - Yahoo Finance
Franklin Resources Inc. Sells 1,820,114 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics (NASDAQ:CYTK) Price Target Raised to $82.00 - MarketBeat
Cytokinetics CFO to assume additional role after officer departs By Investing.com - Investing.com Australia
Cytokinetics CFO to assume additional role after officer departs - Investing.com India
Geode Capital Management LLC Raises Position in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Wendall Wierenga Sells 742 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - MarketBeat
Cytokinetics director Wendall Wierenga sells $36,068 in stock By Investing.com - Investing.com Canada
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):